IN2014MU00303A - - Google Patents

Download PDF

Info

Publication number
IN2014MU00303A
IN2014MU00303A IN303MU2014A IN2014MU00303A IN 2014MU00303 A IN2014MU00303 A IN 2014MU00303A IN 303MU2014 A IN303MU2014 A IN 303MU2014A IN 2014MU00303 A IN2014MU00303 A IN 2014MU00303A
Authority
IN
India
Prior art keywords
pharmaceutical composition
relates
abiraterone
abstract
preparing
Prior art date
Application number
Other languages
English (en)
Inventor
Geena Malhotra
Preeti Raut
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to PCT/GB2015/050175 priority Critical patent/WO2015114314A1/en
Priority to IN303MU2014 priority patent/IN2014MU00303A/en
Publication of IN2014MU00303A publication Critical patent/IN2014MU00303A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
IN303MU2014 2014-01-28 2015-01-27 IN2014MU00303A (hr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/GB2015/050175 WO2015114314A1 (en) 2014-01-28 2015-01-27 Pharmaceutical composition comprising abiraterone
IN303MU2014 IN2014MU00303A (hr) 2014-01-28 2015-01-27

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN303MU2014 IN2014MU00303A (hr) 2014-01-28 2015-01-27

Publications (1)

Publication Number Publication Date
IN2014MU00303A true IN2014MU00303A (hr) 2015-09-11

Family

ID=52462940

Family Applications (1)

Application Number Title Priority Date Filing Date
IN303MU2014 IN2014MU00303A (hr) 2014-01-28 2015-01-27

Country Status (2)

Country Link
IN (1) IN2014MU00303A (hr)
WO (1) WO2015114314A1 (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
US20190209469A1 (en) * 2016-08-20 2019-07-11 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
DK3660004T3 (da) 2016-10-11 2023-05-08 Arvinas Operations Inc Forbindelser og fremgangsmåder til målrettet degradering af androgenreceptor
US11865215B2 (en) 2018-04-26 2024-01-09 Synthon B.V. Tablet compositions comprising abiraterone acetate
WO2020126017A1 (en) * 2018-12-20 2020-06-25 Pharmaceutical Oriented Services Ltd Dosage form containing abiraterone acetate
US20220257613A1 (en) * 2019-07-15 2022-08-18 Shilpa Medicare Ltd Dispersible tablets of abiraterone acetate
WO2021081108A1 (en) * 2019-10-22 2021-04-29 Arvinas Operations, Inc. Methods of treating prostate cancer
CN113384532B (zh) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 一种cyp17抑制剂固体分散体及其制备方法
EP3944860A1 (en) * 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CN115475172B (zh) * 2021-06-15 2023-12-01 北京泰德制药股份有限公司 一种含有阿比特龙或其药用盐的药用组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ608380A (en) * 2010-10-01 2014-10-31 Cipla Ltd Pharmaceutical composition comprising deferasirox
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
BR112015023629A8 (pt) * 2013-03-15 2023-04-11 Iceutica Inc Formulação de acetato de abiraterona

Also Published As

Publication number Publication date
WO2015114314A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
MX2023008686A (es) Polinucleotidos moduladores.
PL3616720T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu
IN2014MU00303A (hr)
TW201613901A (en) New compounds
MX2018014154A (es) Polinucleotidos moduladores.
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
GB2541571A (en) Pharmaceutical compositions
MX2016011862A (es) Inhibidores de c5a para el tratamiento de la neumonia viral.
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
MX2017002489A (es) Agentes terapeuticos humanos.
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
MX2018003563A (es) Nuevos compuestos.
PH12016501841A1 (en) Immunosuppressant formulation
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2020000135A (es) Nuevos compuestos de quinolinona.
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
ZA201703467B (en) Methods of treating ocular conditions
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MX2017009608A (es) Compuestos anticancerigenos.
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
IN2014MU00495A (hr)
GB201719584D0 (en) Pharmaceutical compositions for the treatment of cancer
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro